A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Cosmetic Peptides: SNAP-8

SNAP-8 is the trade name for acetyl octapeptide-3, a cosmetic ingredient designed to reduce the appearance of expression lines by competing with SNAP-25 in the SNARE complex. Its limit is the skin barrier: at about 1,075 Da and highly hydrophilic, very little of a topical dose reaches the tissue where the mechanism would operate.

Structure and mechanism

Acetyl octapeptide-3 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) is an eight-residue extension of acetyl hexapeptide-8 (Argireline), both developed by Lipotec, now part of Lubrizol. The sequence mimics the N-terminal end of SNAP-25, a protein of the SNARE complex that drives vesicle fusion and acetylcholine release at the neuromuscular junction. By competing for a place in the complex, the peptide is proposed to destabilize it and reduce neurotransmitter release in vitro. N-terminal acetylation and C-terminal amidation increase stability against exopeptidases. The mechanism is distinct from botulinum toxin, which cleaves SNAP-25 enzymatically.

Regulatory status

Acetyl octapeptide-3 is a cosmetic ingredient listed in the EU CosIng database, and it is used in cosmetics in the United States, Canada, Korea and elsewhere. Claims must stay within appearance: "reduces the appearance of expression lines" is cosmetic; "relaxes muscles" or "blocks nerve signals" describes a drug effect on body function and would move the product into drug regulation in the United States. It is not a drug, not a botulinum toxin, and not on the WADA Prohibited List. Vegalab uses peptide actives within Beauty Science cosmetic formulations.

Evidence and the penetration problem

Efficacy evidence consists mainly of manufacturer in vitro assays and small vehicle-controlled studies of wrinkle depth, plus the published in vitro and clinical work on the parent hexapeptide. Independent data are limited. Penetration is the practical constraint. Molecules above roughly 500 Da cross intact stratum corneum poorly, and an in vitro human skin study of acetyl hexapeptide-8 found only a small fraction retained in the skin, with none detected in the receptor fluid. A longer, similarly hydrophilic octapeptide faces the same or greater barrier. Formulation, not concentration, decides whether the peptide reaches its target.

Key facts

Acetyl hexapeptide-8, the parent of SNAP-8, mimics the SNAP-25 N-terminus and inhibits neurotransmitter release in vitro (Blanes-Mira et al. 2002, Int J Cosmet Sci)
Compounds above about 500 Da penetrate intact skin poorly (Bos and Meinardi 2000, Exp Dermatol)
In vitro, acetyl hexapeptide-8 showed minimal skin retention and no detectable receptor fluid penetration from a cosmetic formulation (Kraeling et al. 2015, Cutan Ocul Toxicol)
Acetyl octapeptide-3 is listed as a cosmetic ingredient (European Commission CosIng database)

How our delivery technology applies

SNAP-8 needs penetration and protection, not solubility. A multi-layer particle can hold the peptide in a lipid-compatible shell that partitions into the stratum corneum lipid matrix, protect it from skin surface proteases, and release it gradually in the upper epidermis. The endpoint is measurable: Franz cell penetration and skin retention against the free peptide at equal concentration, before any appearance claim is made.

Brands and formulators can request encapsulated peptide samples through Beauty Science.